The Lynx Group, a Cranbury-based alliance of medical and educational companies, announced on Thursday it has acquired Upstream Partners to establish a pharmaceutical and biotechnology division.
“Through this acquisition, customers of both companies will be able to interact with and receive expert advice in all areas of the pharmaceutical and biotech space—prelaunch, launch readiness, go-to-market strategies, and life cycle management—with viewpoints from all stakeholders involved in the care of patients,” Brian Tyburski, CEO, TLG, said.
Lynx said the division will provide clients market-informed insights throughout the product life cycle to ensure success.
“It’s our shared belief that offering our combined pre- and post-market insights, which are sourced from deep channel experience and our relationships with key opinion influencers, is the only way to survive and prosper in the present oncology ecosystem,” Burt Zweigenhaft, managing partner, Upstream Partners, said.
Financial and other terms were not disclosed.
